Sarah Clare

ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands.

Asterion Ltd. develops novel therapeutic products. It offers drugs for patients with chronic, debilitating diseases. The company was founded by Richard John Martin Ross, Peter Artymiuk and Jon R. Sayers in 2001 and is headquartered in Sheffield, the United Kingdom.

NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands.

NightBalance BV develops and markets sensor-devices for the treatment of sleep apnea. It offers sleep position trainer, a small and light aid which can be worn around the chest with an ergonomic band. The firm's a sleep position sensor which gradually and comfortably trains patients using vibrations to not sleep on their back. The company was founded by Eline van Beest and Thijs van Oorschot in 2009 and is headquartered in The Hague, the Netherlands.

Audion Therapeutics BV is a biopharmaceutical firm. It specializes in the discovery, development, and commercialization of drugs and delivery technologies for the treatment of diseases affecting the ear, including hearing loss. The company was founded by Rolf Jan Rutten, Albert Edge, and Helmuth van Es and is headquartered in Amsterdam, the Netherlands.

Emergent Product Development (UK) Ltd. develops oral vaccines for typhoid, traveler's diarrhea, hepatitis B, and anthrax. It also develops vaccines for meningitis and another for streptococcal infections for infants. The company is a biotechnology company focused on harnessing the immune system to treat and prevent disease in areas of significant unmet clinical needs. It was founded in 1996 and is located in Wokingham, UK.

ViCentra BV engages in the development of medical devices. It focuses in creating devices for diabetes patients. The company was founded by Tim Oakes and Joseph John Cefai in 2013 and is headquartered in Utrecht, the Netherlands.

INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam.

Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom.

BD Solutions Ltd. Provides computer support and services. The company is headquartered in London, the United Kingdom.

Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue.

Doctrin AB offers consultancy services within healthcare sector. It offers digital solutions that enable healthcare providers to prioritize, treat, and follow-up with their patients. The company was founded by Per Eriksson, Ashkan Labaf, Magnus Liungman, and Carslo Lorente in 2016 and is headquartered in Stockholm, Sweden.

Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA.

ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021.

SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden.

HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland.

Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.

Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands.

Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom.

Amgen Ltd. operates as a biotechnology firm. It engages in the research and development of human therapeutics to treat illnesses. The company was founded on March 1, 1989 and is headquartered in Cambridge, the United Kingdom.

My Goodness Ltd. produces sports drinks. It contains electrolytes, carbohydrates and other nutrients which are essential for athletes before, after and during exercise. The company was founded by Stuart Jeffreys and Jeremy Martin in 2003 and is headquartered in London, the United Kingdom.

UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom.

Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes.

Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom.

Hamilton Pharmaceuticals, Inc. develops and supplies pharmaceuticals. It also develops and commercializes novel medical treatments for central nervous system disease. The company was founded in April 2004 and is headquartered in Washington, DC.

Part of Helixmith Co., Ltd., Genebiotech Co., Ltd. is a South Korean company that develops gene and cell-based machines. The company is based in Seoul, South Korea. Genebiotech Co. was acquired by Helixmith Co., Ltd. on May 30, 2006.

Cellzome Ltd. engages in the research, development, and manufacture of pharmaceutical products. It provides kinase-targeted drugs to treat inflammatory diseases. The company was founded by Gitte Neubauer on December 22, 2003 and is headquartered in Middlesex, the United Kingdom.